{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:52:25Z","timestamp":1767495145125,"version":"3.40.4"},"reference-count":25,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chemotherapy"],"published-print":{"date-parts":[[2023]]},"abstract":"<jats:p>Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the standard and curative treatment strategy for patients with hematologic malignancies. Recently, decitabine-included regimens have been investigated by several studies including ours, which may prevent relapse of primary malignant diseases. Methods: This study was to retrospectively evaluate a 7-day decitabine-included regimen with reduced dose of idarubicin for patients with hematologic malignancies who underwent allo-HSCT. Results: A total of 84 patients were enrolled, including 24 cases in 7-day and 60 cases in 5-day decitabine groups, respectively. Patients conditioned with 7-day decitabine regimen showed accelerated neutrophil (12.05 \u00b1 1.97 vs. 13.86 \u00b1 3.15; u = 9.309, p &amp;lt; 0.001) and platelet (16.32 \u00b1 6.27 vs. 21.37 \u00b1 8.57; u = 8.887, p &amp;lt; 0.001) engraftment compared with those treated with 5-day decitabine regimen. Patients in the 7-day decitabine group showed a significantly lower incidence rate of total (50.00% [12\/24] versus 78.33% [47\/60]; \u03c72 = 6.583, p = 0.010) and grade III or above (4.17% [1\/24] vs. 31.67% [19\/60]; \u03c72 = 7.147, p = 0.008) oral mucositis compared to those in the 5-day decitabine group. However, the occurrence of other major complications post-allo-HSCT and outcomes of patients in these two groups were comparable. Conclusion: These results demonstrate that this 7-day decitabine-contained new conditioning regimen seems to be feasible and safe for patients with myeloid neoplasms who receive allo-HSCT, and a large-scale prospective study is needed to confirm the findings of this study. <\/jats:p>","DOI":"10.1159\/000530381","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T21:00:37Z","timestamp":1680123637000},"page":"143-154","source":"Crossref","is-referenced-by-count":2,"title":["A 7-Day Decitabine-Included Conditioning Regimen Accelerated Donor Hematopoietic Engraftment while Reduced the Occurrence of Mucositis without Interfering with Prognosis"],"prefix":"10.1159","volume":"68","author":[{"given":"Yuan Yuan","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Long","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeng Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi Geng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing Zhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian Feng","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei Hua","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao Ling","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Er Lie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming Zhe","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"doi-asserted-by":"publisher","key":"ref1","DOI":"10.1182\/blood-2010-06-284349"},{"doi-asserted-by":"publisher","key":"ref2","DOI":"10.2991\/chi.k.210826.001"},{"doi-asserted-by":"publisher","key":"ref3","DOI":"10.1186\/s13045-021-01159-2"},{"doi-asserted-by":"publisher","key":"ref4","DOI":"10.1182\/blood-2009-03-213298"},{"doi-asserted-by":"publisher","key":"ref5","DOI":"10.1016\/S1470-2045(13)70512-6"},{"doi-asserted-by":"publisher","key":"ref6","DOI":"10.1182\/blood-2014-10-605238"},{"doi-asserted-by":"publisher","key":"ref7","DOI":"10.2147\/CMAR.S229768"},{"doi-asserted-by":"publisher","key":"ref8","DOI":"10.1016\/j.bbmt.2019.09.001"},{"doi-asserted-by":"publisher","key":"ref9","DOI":"10.1016\/j.bbmt.2015.09.001"},{"doi-asserted-by":"publisher","key":"ref10","DOI":"10.1002\/1097-0142(19810101)47:1%3c207::aid-cncr2820470134%3e3.0.co;2-6"},{"doi-asserted-by":"publisher","key":"ref11","DOI":"10.1038\/bmt.2013.138"},{"doi-asserted-by":"publisher","key":"ref12","DOI":"10.1080\/10428190701493910"},{"doi-asserted-by":"publisher","key":"ref13","DOI":"10.1002\/cncr.21792"},{"doi-asserted-by":"publisher","key":"ref14","DOI":"10.1200\/JCO.2009.23.9178"},{"doi-asserted-by":"publisher","key":"ref15","DOI":"10.3324\/haematol.2011.048231"},{"doi-asserted-by":"publisher","key":"ref16","DOI":"10.1080\/17474086.2017.1346470"},{"doi-asserted-by":"publisher","key":"ref17","DOI":"10.1182\/blood.2020008477"},{"doi-asserted-by":"publisher","key":"ref18","DOI":"10.1016\/j.bbmt.2015.05.026"},{"doi-asserted-by":"publisher","key":"ref19","DOI":"10.3389\/fonc.2021.710545"},{"doi-asserted-by":"publisher","key":"ref20","DOI":"10.1016\/j.leukres.2020.106419"},{"doi-asserted-by":"publisher","key":"ref21","DOI":"10.1038\/s41409-021-01238-5"},{"doi-asserted-by":"publisher","key":"ref22","DOI":"10.1111\/scd.12525"},{"doi-asserted-by":"publisher","key":"ref23","DOI":"10.1200\/JCO.2001.19.8.2201"},{"doi-asserted-by":"publisher","key":"ref24","DOI":"10.1080\/01635581.2018.1412476"},{"doi-asserted-by":"publisher","key":"ref25","DOI":"10.1007\/s10620-011-1922-5"}],"container-title":["Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/che\/article-pdf\/68\/3\/143\/3999137\/000530381.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/che\/article-pdf\/68\/3\/143\/3999137\/000530381.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T15:23:32Z","timestamp":1745421812000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000530381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":25,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,9,12]]},"published-print":{"date-parts":[[2023,9,19]]}},"URL":"https:\/\/doi.org\/10.1159\/000530381","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.22352644","asserted-by":"subject"}]},"ISSN":["0009-3157","1421-9794"],"issn-type":[{"type":"print","value":"0009-3157"},{"type":"electronic","value":"1421-9794"}],"subject":[],"published":{"date-parts":[[2023]]}}}